thyroid cancer
Local Coverage Determinations Roundup: Veracyte, Sonic Healthcare USA, Tempus
A roundup of local coverage determinations from Medicare administrative contractors.
Thyroid Cancer Prognostic Signature Developed Using Microenvironment Profiles
Researchers used exome sequencing, RNA sequencing, and other approaches to create a "molecular aggression and prediction" score linked to patient outcomes.
Veracyte Q1 Revenues up 22 Percent as Firm Beats Analyst Estimates
The company's testing revenues rose 29 percent in Q1 thanks to increased adoption of its Decipher Prostate and Afirma tests.
Veracyte Ramps up Clinical Evidence Generation, Driving Gains in Prostate and Thyroid Test Business
Premium
The company reported significant revenue growth for Q4 2022, which it attributed to its success in driving clinical test adoption.
While Geisinger sees value in identifying at-risk patients and diagnosing cancer early, some experts are concerned about overtreatment.
Jan 31, 2020
Dec 20, 2019